Kezar Life Sciences President & CSO Christopher Kirk resigns; internal promotions announced

Kezar Life Sciences, Inc.

Christopher Kirk, Ph.D. resigns as President and CSO effective April 21, 2023 for personal reasons; will remain on Board as strategic advisor.
Neel Anand, DPhil promoted to SVP, Research and Drug Discovery; Kieron Wesson, Ph.D. promoted to SVP, CMC and Supply Chain.
Both new SVPs report to CEO John Fowler as part of the company's succession plan.

item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Christopher Kirk

President and Chief Scientific Officer

KZR · Kezar Life Sciences, Inc.

Effective: 2023-04-21
Filed: February 28, 2023, 6:59 PM ET

On February 27, 2023, Christopher Kirk, Ph.D., President, Chief Scientific Officer and member of the Board of Directors (the “Board”) of Kezar Life Sciences, Inc. (the “Company”), provided notice of his intention to resign from the positions of President and Chief Scientific Officer of the Company for personal reasons, effective April 21, 2023 (the “Resignation Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Christopher Kirk resigned as President and Chief Scientific Officer at Kezar Life Sciences, Inc..

Action: resigned
Role: President and Chief Scientific Officer

Exact text from the filing

On February 27, 2023, Christopher Kirk, Ph.D., President, Chief Scientific Officer and member of the Board of Directors (the “Board”) of Kezar Life Sciences, Inc. (the “Company”), provided notice of his intention to resign from the positions of President and Chief Scientific Officer of the Company for personal reasons, effective April 21, 2023 (the “Resignation Date”).

View on SEC.gov

Kezar Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-005140

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.